Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055872 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4060539 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4055590 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4066022 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4055765 | 0.87 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4057892 | 0.86 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4055419 | 0.86 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4053638 | 0.83 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4056599 | 0.81 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4061927 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| EP-1751159-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005105803-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245546-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-03 | — | — | US | claimed |
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1751159-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105803-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245546-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245546-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.